Ahtesham Ali
Acute Care · El Paso, TXNPI 1356988117
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,221 of the $14,051 with a category attached, or 87.0%. It is spread thinly across 40 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 547 payments — averaging $25.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Biogen$1K
- Neurocrine Biosciences, Inc.$1K
- UCB, Inc.$1K
- AbbVie$917
- Argenx US, Inc.$623
- plus $7K from 34 others
What the payments were for
- Travel & lodging$1,1328%
- Food & beverage$12,22187%
- Education$6985%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 20 | $1,503 |
| Biogen | 55 | $1,380 |
| Neurocrine Biosciences, Inc. | 60 | $1,256 |
| UCB, Inc. | 50 | $1,138 |
| AbbVie(2 entities) | 71 | $917 |
| Argenx US, Inc. | 12 | $623 |
| Amgen(2 entities) | 26 | $604 |
| AstraZeneca | 9 | $561 |
| Novartis | 23 | $558 |
| Medtronic | 8 | $529 |
| Teva Pharmaceuticals USA, Inc. | 19 | $472 |
| Lundbeck LLC | 10 | $341 |
| Biohaven Pharmaceutical Holding Company Ltd. | 16 | $331 |
| Lilly USA, LLC | 29 | $330 |
| Jazz Pharmaceuticals Inc. | 14 | $319 |
| EMD Serono, Inc. | 12 | $306 |
| Sanofi | 5 | $282 |
| Pfizer | 18 | $267 |
| SK Life Science, Inc. | 8 | $257 |
| US Oncology Corporate, Inc. | 4 | $246 |
| Neurelis, Inc. | 11 | $232 |
| Genentech USA, Inc. | 8 | $222 |
| Amneal Pharmaceuticals LLC | 14 | $195 |
| Biotronik Inc. | 4 | $175 |
| Axsome Therapeutics, Inc. | 6 | $155 |
| Averitas Pharma Inc. | 1 | $138 |
| Kyowa Kirin, Inc. | 7 | $126 |
| Harmony Biosciences LLC | 3 | $100 |
| Philips North America LLC | 2 | $66 |
| Greenwich Biosciences, Inc. | 4 | $64 |
| CSL Behring | 3 | $59 |
| Octapharma USA, Inc. | 1 | $55 |
| Eisai Inc. | 3 | $50 |
| Catalyst Pharmaceuticals, Inc. | 2 | $42 |
| GE HealthCare | 2 | $36 |
| ANI Pharmaceuticals, Inc. | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| TG Therapeutics, Inc. | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| GRT US Holding, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,051 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 27 | $241,543 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 28 | $137,975 |
| VumerityDiroximel Fumarate | 11 | $110,446 |
| AustedoDeutetrabenazine | 13 | $95,122 |
| Nurtec OdtRimegepant Sulfate | 85 | $91,284 |
| UbrelvyUbrogepant | 35 | $52,669 |
| BotoxOnabotulinumtoxina | 38 | $46,288 |
| RytaryCarbidopa/Levodopa | 47 | $42,302 |
| Emgality PenGalcanezumab-Gnlm | 54 | $37,458 |
| OngentysOpicapone | 25 | $29,088 |
| QuliptaAtogepant | 19 | $26,632 |
| Aimovig AutoinjectorErenumab-Aooe | 20 | $14,816 |
| Memantine Hcl | 771 | $13,886 |
| Emgality SyringeGalcanezumab-Gnlm | 15 | $11,614 |
| NeuproRotigotine | 13 | $10,981 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $1,256 | $270,63252 claims |
| AbbVieUbrelvy, Botox, Qulipta | $917 | $125,58992 claims |
| BiogenVumerity | $1,380 | $110,44611 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $472 | $95,12213 claims |
| PfizerNurtec Odt | $267 | $91,28485 claims |
| Amneal Pharmaceuticals LLCRytary | $195 | $42,30247 claims |
| UCB, Inc.Neupro | $1,138 | $10,98113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,323 acute care providers in Texas.
Other acute care in El Paso
- Laura WilsonEl Paso$32K
- Adriana SanchezEl Paso$11K
- Haydee BirkhimerEl Paso$10K
- Patricia DandEl Paso$9K
- Dora CarcobaEl Paso$8K
- Jennifer PilotteDallas$232K
- Christie MorrisonSan Antonio$225K
- Amanda BradleyDallas$85K
- Kim HuynhCypress$29K
- Martha LibertyDallas$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.